Taipei, Taiwan, December 7th, 2023 –– Lotus Pharmaceutical (1795:TT), a leading global pharmaceutical company, announces the delivery of its first shipment of Lenalidomide Capsules (generic version of Revlimid®) in 2.5mg and 5mg strengths to the Japanese market. This marks a significant milestone in Lotus' strategic expansion aimed at making medicine more accessible worldwide.
This momentous achievement is the result of a collaborative effort with Fuji Pharma Co., Ltd. ("Fuji"). The partnership with Fuji Pharma has played a pivotal role in these significant strides forward, solidifying Lotus' commitment to forging collaborations that contribute to the advancement of healthcare solutions.
Lenalidomide has been one of the major growth drivers for Lotus, fueling continuous growth in the last couple of years. After its successful launch in Europe in2022, Lenalidomide officially entered the U.S. market in the 3rd quarter of 2022. By early 2023, Lenalidomide had also been launched in Brazil through collaboration with partners and now it had started a new chapter in Japan. Leveraging global partnerships and its own commercial network. Following its success in various markets, Lenalidomide continues to make a global impact, showcasing Lotus' dedication to providing high-quality medications on a broader scale.
According to the IMS data, Japan is the third-largest pharmaceutical market globally in terms of spending. The collaboration with Fuji has opened doors to the dynamic Japanese pharmaceutical landscape. As per IQVIA data, the total market size of Lenalidomide in Japan was around US$300 million. This presents an exciting opportunity for Lotus to introduce a strategic pipeline in Japan.
Petar Vazharov, Lotus' Chief Executive Officer, expressed his enthusiasm about this significant milestone, stating, " Successful delivery of first Lenalidomide shipment to Japan represents a major milestone for Lotus and reaffirms our commitment to supply more accessible anti- cancer medicines globally. As a global leader in the development of oral oncology products we are very pleased to expand access to our high-quality products to the patients in Japan. I would like to thank Lotus and Fuji teams for the excellent collaboration and execution."
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Investor and Media Relations
Susan Liao, Head of Investor Relations
+886 2 2700 5908